MYBL2 and prostate carcinoma: The transcription factor MYBL2 impacts both in vitro hormone‐sensitive prostate cancer sensitivity to androgen deprivation and taxanes and lower levels are associated with better clinical outcomes in men with hormone‐sensitive prostate cancer.